Literature DB >> 28824048

Lower Level of Low Density Lipoprotein Cholesterol is Associated with a Higher Increase in the Fractional Flow Reserve in Patients with Fixed-dose Rosuvastatin.

Takehiro Hashikata1, Taiki Tojo1, Yusuke Muramatsu1, Toshimitsu Sato1, Ryota Kakizaki1, Teruyoshi Nemoto1, Kazuhiro Fujiyoshi1, Sayaka Namba1, Lisa Kitasato1, Takuya Hashimoto1, Ryo Kameda1, Takao Shimohama1, Minako Yamaoka-Tojo2, Junya Ako1.   

Abstract

AIM: Fractional flow reserve (FFR) reflects on the diffuse atherosclerosis per coronary artery. It is unknown whether the statin therapy affects long term FFR after stenting. The aim of this study was to evaluate the long term FFR after stent implantation in patients who are intaking fixed-dose rosuvastatin.
METHODS: A total of 22 patients with stable angina pectoris were enrolled. The values of FFR were measured before, immediately after, and 18 months after (follow-up day) the implantation of everolimus eluting stent (EES; Promus ElementTM or Promus Element PlusTM). A fixed dose of rosuvastatin at 5 mg/day was administrated to all patients.
RESULTS: Of the 22 patients, 2 were excluded because of adverse effect of rosuvastatin and in-stent total occlusion after EES implantation. Overall, the values of FFR immediately after and 18 months after EES implantation did not show significant change (from 0.90±0.05 to 0.88±0.06, p=0.16). However, there was a significant negative correlation between low density lipoprotein (LDL) cholesterol level at follow-up day and changes in the value of FFR (p=0.01, r =-0.74). There was an increase in the FFR value after stenting in 8 out of 9 patients with LDL cholesterol level below 75 mg/dl (area under the curve 0.92, p=0.0005).
CONCLUSIONS: LDL cholesterol level was associated with the change in the FFR value in patients following stent implantation. Lower LDL cholesterol tended to improve in the long-term FFR, underscoring the importance of lowering LDL cholesterol to prevent the progression of coronary atherosclerosis.

Entities:  

Keywords:  Coronary pressure; Everolimus eluting stent; Functional ischemia; Statin

Mesh:

Substances:

Year:  2017        PMID: 28824048      PMCID: PMC5868509          DOI: 10.5551/jat.39560

Source DB:  PubMed          Journal:  J Atheroscler Thromb        ISSN: 1340-3478            Impact factor:   4.928


  38 in total

1.  Invasive assessment of the coronary microcirculation: superior reproducibility and less hemodynamic dependence of index of microcirculatory resistance compared with coronary flow reserve.

Authors:  Martin K C Ng; Alan C Yeung; William F Fearon
Journal:  Circulation       Date:  2006-04-24       Impact factor: 29.690

2.  Novel index for invasively assessing the coronary microcirculation.

Authors:  William F Fearon; Leora B Balsam; H M Omar Farouque; Anthony D Caffarelli; Robert C Robbins; Peter J Fitzgerald; Paul G Yock; Alan C Yeung
Journal:  Circulation       Date:  2003-06-23       Impact factor: 29.690

3.  The relationship between intravascular ultrasound-derived percent total atheroma volume and fractional flow reserve in the intermediate stenosis of proximal or middle left anterior descending coronary artery.

Authors:  Xiong Jie Jin; Seung-Jea Tahk; Hyoung-Mo Yang; Hong-Seok Lim; Myeong-Ho Yoon; So-Yeon Choi; Byoung-Joo Choi; Gyo-Seung Hwang; Kyoung-Woo Seo; Jeoung-Sook Shin; You-Hong Lee; Yong-Woo Choi; Se-Jun Park; Jin-Sun Park; Joon-Han Shin
Journal:  Int J Cardiol       Date:  2015-03-04       Impact factor: 4.164

4.  Relationship between fractional flow reserve and residual plaque volume and clinical outcomes after optimal drug-eluting stent implantation: insight from intravascular ultrasound volumetric analysis.

Authors:  Tsuyoshi Ito; Tomomitsu Tani; Hiroshi Fujita; Nobuyuki Ohte
Journal:  Int J Cardiol       Date:  2014-08-01       Impact factor: 4.164

5.  A prospective, randomized evaluation of a novel everolimus-eluting coronary stent: the PLATINUM (a Prospective, Randomized, Multicenter Trial to Assess an Everolimus-Eluting Coronary Stent System [PROMUS Element] for the Treatment of Up to Two de Novo Coronary Artery Lesions) trial.

Authors:  Gregg W Stone; Paul S Teirstein; Ian T Meredith; Bruno Farah; Christophe L Dubois; Robert L Feldman; Joseph Dens; Nobuhisa Hagiwara; Dominic J Allocco; Keith D Dawkins
Journal:  J Am Coll Cardiol       Date:  2011-04-04       Impact factor: 24.094

6.  Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial.

Authors:  Helen M Colhoun; D John Betteridge; Paul N Durrington; Graham A Hitman; H Andrew W Neil; Shona J Livingstone; Margaret J Thomason; Michael I Mackness; Valentine Charlton-Menys; John H Fuller
Journal:  Lancet       Date:  2004 Aug 21-27       Impact factor: 79.321

7.  Fractional flow reserve with dobutamine challenge and coronary microvascular endothelial dysfunction in symptomatic myocardial bridging.

Authors:  Satoshi Yoshino; Andrew Cassar; Yoshiki Matsuo; Joerg Herrmann; Rajiv Gulati; Abhiram Prasad; Ryan J Lennon; Lilach O Lerman; Amir Lerman
Journal:  Circ J       Date:  2014-01-24       Impact factor: 2.993

8.  Intravenous administration of adenosine triphosphate disodium during primary percutaneous coronary intervention attenuates the transient rapid improvement of myocardial wall motion, not myocardial stunning, shortly after recanalization in acute anterior myocardial infarction.

Authors:  Takehito Tokuyama; Tadamichi Sakuma; Chikaaki Motoda; Tomoharu Kawase; Ryou Takeda; Shinji Mito; Hiromichi Tamekiyo; Masaya Otsuka; Tomokazu Okimoto; Mamoru Toyofuku; Hidekazu Hirao; Yuji Muraoka; Hironori Ueda; Yoshiko Masaoka; Yasuhiko Hayashi
Journal:  J Cardiol       Date:  2009-07-21       Impact factor: 3.159

9.  Cholesterol Lowering in Intermediate-Risk Persons without Cardiovascular Disease.

Authors:  Salim Yusuf; Jackie Bosch; Gilles Dagenais; Jun Zhu; Denis Xavier; Lisheng Liu; Prem Pais; Patricio López-Jaramillo; Lawrence A Leiter; Antonio Dans; Alvaro Avezum; Leopoldo S Piegas; Alexander Parkhomenko; Katalin Keltai; Matyas Keltai; Karen Sliwa; Ron J G Peters; Claes Held; Irina Chazova; Khalid Yusoff; Basil S Lewis; Petr Jansky; Kamlesh Khunti; William D Toff; Christopher M Reid; John Varigos; Gregorio Sanchez-Vallejo; Robert McKelvie; Janice Pogue; Hyejung Jung; Peggy Gao; Rafael Diaz; Eva Lonn
Journal:  N Engl J Med       Date:  2016-04-02       Impact factor: 91.245

10.  Efficacy of Statin Therapy in Inducing Coronary Plaque Regression in Patients with Low Baseline Cholesterol Levels.

Authors:  Kohei Wakabayashi; Tsuyoshi Nozue; Shingo Yamamoto; Shinichi Tohyama; Kazuki Fukui; Shigeo Umezawa; Yuko Onishi; Tomoyuki Kunishima; Akira Sato; Shogo Miyake; Yoshihiro Morino; Takao Yamauchi; Toshiya Muramatsu; Kiyoshi Hibi; Mitsuyasu Terashima; Hiroshi Suzuki; Ichiro Michishita
Journal:  J Atheroscler Thromb       Date:  2016-03-31       Impact factor: 4.928

View more
  3 in total

1.  Influence of intensive lipid-lowering on CT derived fractional flow reserve in patients with stable chest pain: Rationale and design of the FLOWPROMOTE study.

Authors:  Martin B Mortensen; Niels-Peter Sand; Martin Busk; Jesper M Jensen; Erik L Grove; Damini Dey; Nadia Iraqi; Adam Updegrove; Tim Fonte; Ole N Mathiassen; Susanne Hosbond; Hans E Bøtker; Jonathon Leipsic; Jagat Narula; Bjarne L Nørgaard
Journal:  Clin Cardiol       Date:  2022-09-03       Impact factor: 3.287

2.  Effect of Low-Density Lipoprotein Cholesterol Goal Achievement on Vascular Physiology Evaluated by Quantitative Flow Ratio in Patients Who Underwent Percutaneous Coronary Intervention.

Authors:  Long Chen; Qin Chen; Jiaxin Zhong; Zhen Ye; Mingfang Ye; Yuanming Yan; Lianglong Chen; Yukun Luo
Journal:  Front Cardiovasc Med       Date:  2021-06-18

3.  Coronary flow impairment in asymptomatic patients with early stage type-2 diabetes: Detection by FFRCT.

Authors:  Monija Mrgan; Bjarne Linde Nørgaard; Damini Dey; Jørgen Gram; Michael Hecht Olsen; Jeppe Gram; Niels Peter Rønnow Sand
Journal:  Diab Vasc Dis Res       Date:  2020 Sep-Oct       Impact factor: 3.291

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.